Alexion Pharmaceuticals, Inc.
Cheshire
Dr. Leonard Bell, CEO
http://www.alxn.com/
Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company
focused on developing life-transforming therapies for patients with
severe and life-threatening diseases that are also ultra-rare and lack
effective treatment options. Our first commercial product, Soliris®
(eculizumab), is approved in more than 40 countries as a treatment for
patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the
United States, European Union and Canada as a treatment for patients
with atypical hemolytic uremic syndrome (aHUS). Alexion is evaluating
other potential indications for Soliris and is developing additional
highly innovative biotechnology product candidates, which are being
investigated across nine other severe and ultra-rare disorders.
Bio-Med Devices, Inc.
Guilford
Dean
Bennett, III, President
http://www.biomeddevices.com/
Bio-Med Devices, a privately held, ISO registered company, designs,
manufactures and markets a complete line of respiratory products for the
critical care and transport market. This includes ventilators, air
oxygen blenders, breathing circuits, and neonatal resuscitation modules
for several large OEM companies.
Our products are CE marked and marketed worldwide through dealers in
over 90 countries.
Metrum Research Group, LLC
Tariffville
Marc Gastonguay, President & CEO
http://metrumrg.com/
Metrum Research Group (est. 2004) is a global leader in
biomedical modeling and simulation. Metrum Research Group scientists
apply quantitative expertise and proprietary disease model libraries to
support decisions in biomedical R&D programs for pharmaceuticals,
biologic therapeutics, diagnostics, and medical devices. Applications
range across all therapeutic areas, with particular emphasis in
Alzheimer's Disease, bone health, hepatitis-C, multiple sclerosis, pain,
pediatrics and rare disorders. Metrum Research Group is an Inc. 5000
company and has been a Marcum Tech Top 40 winnerfor the past four
years.
